dabrafenib/trametinib combo - FDA Priority Review

RNS Number : 0603O

GlaxoSmithKline PLC

16 September 2013

 



Issued: Monday 16 September 2013, London UK - LSE announcement

GSK receives Priority Review from FDA for dabrafenib/trametinib combination in metastatic melanoma

GlaxoSmithKline plc (LSE:GSK) today announced that the US Food and Drug Administration (FDA) has granted Priority Review designation to its supplemental New Drug Applications (sNDAs) for combined use of Tafinlar^® (dabrafenib) and Mekinist^® (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 E or K mutation. 

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of 8 January 2014 for the Mekinist^®(trametinib) supplement and 9 January 2014 for the Tafinlar^®(dabrafenib) supplement.

The applications are based on data from a randomised Phase I/II study comparing combination therapy with dabrafenib and trametinib to dabrafenib monotherapy in adult patients with BRAF V600E and V600K mutation positive metastatic melanoma.

Use of dabrafenib and trametinib in combination is investigational and not approved anywhere in the world.  On 7 February 2013, GSK announced European regulatory submission for the combined use of dabrafenib and trametinib adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation and the review is ongoing according to standard timelines.

For full US Prescribing Information and Medication Guide and EU Patient Information Leaflet or Summary of Product Characteristics (SPC) for Tafinlar^® and Mekinist^®, please visit http://www.gsk.com/products/index.htm

S M Bicknell

Company Secretary

16 September 2013

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:
UK Media enquiries:	David Mawdsley	[phone]	(London)
	Simon Steel	[phone]	(London)
	David Daley	[phone]	(London)
	Catherine Hartley	[phone]	(London)
US Media enquiries:	Melinda Stubbee	[phone]	(North Carolina)
	Stephen Rea	[phone]	(Philadelphia)
	Bernadette King	[phone]	(Philadelphia)
	Anna Padula	[phone]	(Philadelphia)
Analyst/Investor enquiries:	Ziba Shamsi	+ 44 (0) 20 8047 3289	(London)
	Lucy Budd	[phone]	(London)
	Tom Curry	+ 1 215 751 5419	(Philadelphia)
	Gary Davies	+ 44 (0) 20 8047 5503	(London)
	James Dodwell	+ 44 (0) 20 8047 2406	(London)
	Jeff McLaughlin	+ 1 215 751 7002	(Philadelphia)

Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2012.

 

Registered in England & Wales: No. 3888792

Registered Office: 980 Great West Road Brentford, Middlesex TW8 9GS

 

END

 

 

MSCGGUAABUPWURQ